Why the study?
Does the peptide-based renin inhibitor A-72517 demonstrate oral bioavailability and efficacy in reducing blood pressure and renin activity in animal models?
Does the peptide-based renin inhibitor A-72517 demonstrate oral bioavailability and efficacy in reducing blood pressure and renin activity in animal models?
This preclinical study demonstrates that a peptide-based renin inhibitor can achieve significant oral bioavailability and physiological efficacy, supporting the development of oral peptide-based therapeutics.
Answers are grounded in this paper and cite their sources.
Animal data support oral renin inhibitor feasibility; hypothesis-generating for humans and should not yet change practice.
Peptidic renin inhibitors have been poorly absorbed across the intestine or rapidly eliminated by the liver and have been reported to have oral bioavailabilities of less than 2%. A peptide-based renin inhibitor, A-72517 (molecular mass of 706 daltons), was devised that has oral bioavailabilities of 8, 24, 32, and 53% in the monkey, rat, ferret, and dog, respectively. Dose-related reductions in blood pressure, plasma renin activity, and plasma angiotensin II in parallel with increased plasma drug concentrations were observed after oral administration of A-72517 to conscious, salt-depleted dogs. Thus, peptide-based molecules of sizable molecular mass can be absorbed intact into the systemic circulation of animals. These findings support the potential of peptide-based drugs for oral administration.
No takes yet. Share an insight, caveat, or question.
Kleinert et al. (1992) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: